H-CYTE, Inc. (OTCMKTS:HCYTD – Get Free Report)’s share price was down 49.5% during mid-day trading on Tuesday . The stock traded as low as $2.02 and last traded at $2.02. Approximately 400 shares were traded during trading, an increase of 288% from the average daily volume of 103 shares. The stock had previously closed at $4.00.
H-CYTE Trading Down 49.5 %
The company’s fifty day simple moving average is $2.02 and its 200-day simple moving average is $2.02.
H-CYTE Company Profile
H-CYTE, Inc, a biopharmaceutical company, develops and delivers various treatments for patients with chronic respiratory and pulmonary disorders in the United States. The company develops and implements treatment options in autologous cellular therapy to treat chronic lung disorders. It has a product supply agreement with Rion, LLC to develop and distribute a biologic for chronic obstructive pulmonary disease.
Featured Stories
- Five stocks we like better than H-CYTE
- Top Stocks Investing in 5G Technology
- NVIDIA’s Blackwell Chips Set for Arizona Manufacturing by TSMC?
- Basic Materials Stocks Investing
- Okta: Bullish Signals Suggest a Market Reversal Is Underway
- 5 discounted opportunities for dividend growth investors
- BlackRock Makes Waves With $12B Private Credit Acquisition
Receive News & Ratings for H-CYTE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for H-CYTE and related companies with MarketBeat.com's FREE daily email newsletter.
